Predict your next investment

Hedge Fund
ridgebackcap.com

See what CB Insights has to offer

Investments

28

Portfolio Exits

11

About Ridgeback Capital Management

Ridgeback Capital is a healthcare hedge fund founded by Wayne Holman in 2006. Wayne Holman previously worked at Steve Cohen's subsidiary Sigma Capital. The fund has more than $500 million in AUM.

Ridgeback Capital Management Headquarters Location

430 Park Avenue Floor 12

New York, New York, 10022,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ridgeback Capital Management News

Freenome Inks $300M Series D Round

Dec 7, 2021

This brings the company's total financing to over $800 million since the company was founded in 2014. This round of financing was led by investors Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc. In addition, there were several new biotech institutional investors well-placed to support the company's mission including ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, and other undisclosed funds. Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Ridgeback Capital Management Investments

28 Investments

Ridgeback Capital Management has made 28 investments. Their latest investment was in Quell Therapeutics as part of their Series B on November 11, 2021.

CBI Logo

Ridgeback Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/29/2021

Series B

Quell Therapeutics

$156M

Yes

18

11/9/2021

Series B

Arbor Biotechnologies

$215M

Yes

13

9/23/2021

Series A

Garuda Therapeutics

$72M

Yes

17

7/14/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/29/2021

11/9/2021

9/23/2021

7/14/2021

5/6/2021

Round

Series B

Series B

Series A

Series D

Series B

Company

Quell Therapeutics

Arbor Biotechnologies

Garuda Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$156M

$215M

$72M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

18

13

17

10

10

Ridgeback Capital Management Portfolio Exits

11 Portfolio Exits

Ridgeback Capital Management has 11 portfolio exits. Their latest portfolio exit was Senti Biosciences on December 20, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/20/2021

Acq - Pending

$99M

3

10/8/2021

IPO

$99M

Public

9

7/23/2021

IPO

$99M

Public

10

12/11/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/28/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/20/2021

10/8/2021

7/23/2021

12/11/2020

3/28/2019

Exit

Acq - Pending

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

9

10

10

10

Ridgeback Capital Management Team

2 Team Members

Ridgeback Capital Management has 2 team members, including former Managing Partner, Moises Israel Abecasis.

Name

Work History

Title

Status

Wayne Holman

Founder

Current

Moises Israel Abecasis

Oquendo Capital, Atlas Capital, and Merrill

Managing Partner

Former

Name

Wayne Holman

Moises Israel Abecasis

Work History

Oquendo Capital, Atlas Capital, and Merrill

Title

Founder

Managing Partner

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.